The relationship of the level of circulating antiangiogenic factors to the clinical manifestations of preeclampsia

Prenatal Diagnosis

Volumn 29, Issue 5, 2008, Pages 464-470

  Kim, Young Nam ^a   Lee, Dae Shim ^a   Jeong, Dae Hoon ^a   Sung, Moon Su ^a   Kim, Ki Tae ^a,b  

^a Inje University College of Medicine   (South Korea)

^b Inje University   (South Korea)

Author keywords

Preeclampsia; Soluble endoglin (seng); Soluble fms like tyrosine kinase 1 (sflt 1)

Indexed keywords

ENDOGLIN; PLACENTAL GROWTH FACTOR; PROTEIN TYROSINE KINASE; SOLUBLE FMS LIKE TYROSINE KINASE 1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GESTATIONAL AGE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; PARITY; PATHOPHYSIOLOGY; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEINURIA;

ADULT; ANGIOGENESIS INHIBITORS; CASE-CONTROL STUDIES; FEMALE; FETAL GROWTH RETARDATION; GESTATIONAL AGE; HUMANS; PRE-ECLAMPSIA; PREGNANCY; PROTEINURIA; SEVERITY OF ILLNESS INDEX; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 66849106737     PISSN: 01973851     EISSN: 10970223     Source Type: Journal    
DOI: 10.1002/pd.2203     Document Type: Article

References (21)

1. Chaiworapongsa T, Romero R, Kim YM, et al. 2005. Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. JMatern Fetal Neonatal Med 17: 3-18.
2. Chan P, Brown M, Simpson JM, Davis G. 2005. Proteinuria in preeclampsia: how much matters? BJOG 112: 280-285.
3. Hall DR, Odendaal HJ, Kirsten GF, Smith J, Grove D. 2000. Expectant management of early onset, severe pre-eclampsia: perinatal outcome. BJOG 107: 1258-1264.
4. Levine RJ, Lam C, Qian C, et al. 2006. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 355: 992-1005.
5. Levine RJ, Maynard SE, Qian C, et al. 2004. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350: 672-683.
6. Livingston JC, Chin R, Haddad B, McKinney ET, Ahokas R, Sibai BM. 2000. Reductions of vascular endothelial growth factor and placental growth factor concentrations in severe preeclampsia. Am J Obstet Gynecol 183: 1554-1557.
7. MacKay AP, Berg CJ, Atrash HK. 2001. Pregnancy-related mortality from preeclampsia and eclampsia. Obstet Gynecol 97: 533-538.
8. Masuyama H, Suwaki N, Nakatsukasa H, Masumoto A, Tateishi Y, Hiramatrsu Y. 2006. Circulating angiogenic factors in preeclamp- sia, gestational proteinuria, and preeclampsia superimposed on chronic glomerulonephritis. Am J Obstet Gynecol 194: 551-556.
9. Maynard SE, Min JY, Merchan J, et al. 2003. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111: 649-658.
10. Menzies J, Magee LA, Macnab YC, et al. 2007. Current CHS and NHBPEP criteria for severe preeclampsia do not uniformly predict adverse maternal or perinatal outcomes. Hypertens Pregnancy 26: 447-462.
11. Ness RB, Roberts JM. 1996. Heterogeneous causes constituting the single syndrome of preeclampsia: a hypothesis and its implications. Am JObstet Gynecol 175: 1365-1370.
12. Ness RB, Sibai BM. 2006. Shared and disparate components of the pathophysiologies of fetal growth restriction and preeclampsia. Am J Obstet Gynecol 195: 40-49.
13. Newman MG, Robichaux AG, Stedman CM, et al. 2003. Perinatal outcomes in preeclampsia that is complicated by massive proteinuria. Am J Obstet Gynecol 188: 264-268.
14. Nishizawa H, Pryor-Koishi K, Kato T, Kowa H, Kurahashi H, Udagawa Y. 2007. Microarray analysis of differentially expressed fetal genes in placental tissue derived from early and late onset severe pre-eclampsia. Placenta 28: 487-497.
15. Ohkuchi A, Hirashima C, Matsubara S, et al. 2007. Alterations in placental growth factor levels before and after the onset of preeclampsia are more pronounced in women with early onset severe preeclampsia. Hypertens Res 30: 151-159.
16. Redman CW, Sargent IL. 2005. Latest advances in understanding preeclampsia. Science 308: 1592-1594. Roberts JM, Hubel CA. 1999. Is oxidative stress the link in the two-stage model of pre-eclampsia? Lancet 354: 788-789.
17. Schiff E, Friedman SA, Stampfer M, Kao L, Barrett PH, Sibai BM. 1996. The importance of urinary protein excretion during conservative management of severe preeclampsia. Am J Obstet Gynecol 175: 1024-1028.
18. Shibata E, Rajakumar A, Powers RW, et al. 2005. Soluble fms- like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor. J Clin Endocrinol Metab 90: 4895-4903.
19. Stillman IE, Karumanchi SA. 2007. The glomerular injury of preeclampsia. J Am Soc Nephrol 18: 2281 -2284.
20. Tsatsaris V, Goffin F, Munaut C, et al. 2003. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab 88: 5555-5563.
21. Venkatesha S, Toporsian M, Lam C, et al. 2006. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 12: 642-649.